Exhibit 99.1 Avantor® Reports Third Quarter 2024 Results • Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7% • Net income of $57.8 million; Adjusted EBITDA of $302.5 million • Diluted GAAP EPS of $0.08; adjusted EPS of $0.26 • Operating cash flow of $244.8 million; free cash flow of $204.0 million RADNOR, Pa. – October 25, 2024 – Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology indust ...

Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7% Net income of $57.8 million; Adjusted EBITDA of $302.5 million Diluted GAAP EPS of $0.08; adjusted EPS of $0.26 Operating cash flow of $244.8 million; free cash flow of $204.0 millionRADNOR, Pa., Oct. 25, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its third fi ...

Avantor and NIBRT have formed a new partnership to supply advanced Masterflex® equipment, essential products, and expert training to foster innovations in biopharma manufacturing RADNOR, Pa., Oct. 23, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced an expanded partnership with the National Institute for Bioprocessing Research and Training (NIBRT). The new ...

Transaction Details - Avantor Inc (AVTR) closed the divestiture of its clinical services business to Audax Private Equity for approximately $650 million [1] - The deal includes kitting, biorepository, and related equipment and ancillaries, collectively known as Clinical Services [3] - The transaction is expected to generate approximately $500 million in after-tax cash proceeds and reduce approximately $50 million in capitalized leases [3] Financial Impact - The divestiture strengthens AVTR's balance sheet and reduces interest expenses [1] - Management plans to use the after-tax proceeds for debt paydown [3] - The deal aligns with AVTR's new operating model and accelerates its business transformation [3] Stock Performance - AVTR shares closed flat at $24.73 following the announcement [2] - Year-to-date, AVTR shares have rallied 8.3%, outperforming the industry's decline of 2.5% [2] - The S&P 500 increased 22.9% during the same period [2] Industry Prospects - The global analytical laboratory service market is estimated to be $472.6 million in 2024 and projected to reach $1,375 million by 2034, growing at a CAGR of 11.3% [4] - Factors driving the market include the growing popularity of point-of-care testing and the adoption of smart lab infrastructure with sensor networks [5] - The divestiture is expected to provide significant impetus to AVTR's lab and production businesses [5] Comparative Stock Analysis - AVTR currently carries a Zacks Rank 3 (Hold) [6] - Better-ranked stocks in the medical space include Boston Scientific (BSX), DaVita (DVA), and Masimo (MASI), each with a Zacks Rank 2 (Buy) [6] - Boston Scientific shares have gained 70.4% in the past year, with EPS estimates remaining constant at $2.40 for 2024 and $2.71 for 2025 [6] - DaVita shares have surged 103.3% in the past year, with 2024 EPS estimates remaining constant at $9.99 [7] - Masimo shares have surged 80.4% in the past year, with 2024 EPS estimates rising 0.3% in the past 30 days [7]

RADNOR, Pa., Oct. 18, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it has closed the divestiture of its clinical services business to Audax Private Equity in a transaction valued at approximately $650 million. Avantor expects the transaction to result in approximately $500 million in after-tax cash proceeds and a reduction of approximately $50 million i ...

Investors looking for stocks in the Medical Services sector might want to consider either Pediatrix Medical Group (MD) or Avantor, Inc. (AVTR) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphas ...

Recognition highlights commitment to Avantor Business System (ABS) principles to enhance customer experienceRADNOR, Pa., Sept. 30, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, announced today that the Company's NuSil brand has received the 2024 North American Daily Kaizen Management award from the Kaizen Institute. NuSil, the leading global provider of high-purity s ...

RADNOR, Pa., Sept. 27, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, will release its third quarter 2024 financial results before the market opens on Friday, October 25, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results.To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Ava ...

Reflects Growing Commitment to Renewable Energy SourcesEnergize virtual power purchase agreement will provide the equivalent of 25GWh of renewable energy annually beginning in 2026Avantor continues to implement global solar installations, with more planned in 2025RADNOR, Pa., Sept. 25, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, has entered into a 10-year virtual p ...

RADNOR, Pa., Sept. 23, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced the Company will deliver multiple scientific presentations and exhibit at BioProcess International 2024, scheduled for September 23-26 in Boston. Over 3,200 biopharmaceutical development and production professionals representing 40-plus countries are expected to attend.Avantor's scientific p ...